|Mr. James J. McGorry||CEO & Director||420.6k||N/A||1956|
|Mr. Thomas W. McNaughton||Sec.||353.63k||N/A||1960|
|Dr. William L. Fodor Ph.D.||Chief Scientific Officer||287.34k||N/A||1959|
|Ms. Ginger A. Abraham-Freel||Director of Quality & Operations||N/A||N/A||N/A|
Biostage, Inc., a biotechnology company, engages in developing bioengineered organ implants based on its Cellframe technology. The company's Cellframe technology comprises a biocompatible scaffold that is seeded with the recipient's own stem cells. It is developing its Cellframe technology to treat life-threatening conditions of the esophagus, bronchus, or trachea. The company was formerly known as Harvard Apparatus Regenerative Technology, Inc. and changed its name to Biostage, Inc. in March 2016. Biostage, Inc. was founded in 2007 and is headquartered in Holliston, Massachusetts.
Biostage, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.